ARTICLES BY MATTHEW PILLAR

• Legal And IP Protection For New Biotechs

  10/31/2023

  Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

• Engineering Antibodies In A Box?

  7/27/2023

  Machines aren’t smart enough to engineer optimal, disease-specific antibodies without data that’s properly generated, captured, and structured. That’s why LabGenius Founder Dr. James Field says the key to success is neither human-derived data, nor machine-enabled design. It’s the organizational engineering feat of bringing the two together.

• Antibody-Drug Conjugates: Increasing Investment In R&D And Partnership

  2/1/2023

  DeciBio’s Antibody-Drug Conjugates 2023 Industry Survey points to progress in ADC development. Respondents anticipate lower regulatory, financial, and R&D barriers as the technology matures. Senior Life Science Expert Joe Daccache, Ph.D. gave us an insider's look at the numbers.

• The Coming Wave Of Radio(bio)pharmaceuticals

  6/13/2022

  Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling technologies improve on previous failures, CEO, CMO, and co-founder Dr. Philip Kantoff is projecting a new wave of activity in the space among biopharmas big and small.

• Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.

  11/28/2021

  Lumen Bioscience's cofounder and CEO, Brian Finrow, J.D., and EVP of production/development, Craig Behnke, Ph.D., discuss the development of therapeutic proteins from readily available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.

• AION Labs’ Challenge To AI Drug Development Innovators

  11/1/2021

  AstraZeneca, Merck, Pfizer, The Israel Biotech Fund, BioMed X Institute, Teva Pharmaceuticals, and Amazon Web Services are teaming up to support the AION Labs mission to inspire innovation in AI-enabled drug discovery and development. Here’s how the consortium created collaboration among fierce competitors.

• Developability: Making Better Bets On Biologic Winners

  10/25/2021

  Developability assessments are objective analyses of a molecule’s therapeutic potential, but their execution is as much art as it is science. AltruBio VP of Technical Development Gene Lee, Ph.D. shares his insight into when, why, and how to go about assessing CMC developability.

• Drug Discovery: Picking The Winners & Losers

  6/18/2021

  Glympse Bio is developing bio-engineered, in-vivo diagnostic technologies that could offer biologics developers earlier insight into target engagement and therapeutic response. That spells big implications on translational research, speed to clinic, and time to market.

• Computational Science: Disruption In Biopharma Discovery

  3/12/2021

  NeuBase Therapeutics CEO Dr. Dietrich Stephan discusses the important role computational drug discovery plays as we emerge from what he characterizes as “a decades-long, multi-billion-dollar chemical engineering escapade with a very low success rate to find one drug.”

• Are Dry Powder Biologics Ready For Primetime?

  9/21/2020

  A new approach to freezing biopharmaceuticals into fine, dry powders holds promise for flexible therapeutic form factors, efficacy improvements, and supply and distribution chain efficiencies. It's a particularly timely development in the age of COVID-19.

• Mechanistic Action: Genesis Of A Biologics Pipeline?

  6/17/2020

  Cue Biopharma President & CSO Anish Suri, Ph.D. tells us why a partnership with The University Of Oxford to visualize the mechanistic action of molecules at the immunological synapse could provide insights that guide future drug discovery and development strategy.

• Precision Medicine In Practice

  6/16/2020

  Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.

• A New Cost Paradigm For CAR Cell Therapies?

  6/12/2020

  Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.